MX2022004027A - Farmaco farmaceutico que contiene derivado de heterocicliden acetamida. - Google Patents

Farmaco farmaceutico que contiene derivado de heterocicliden acetamida.

Info

Publication number
MX2022004027A
MX2022004027A MX2022004027A MX2022004027A MX2022004027A MX 2022004027 A MX2022004027 A MX 2022004027A MX 2022004027 A MX2022004027 A MX 2022004027A MX 2022004027 A MX2022004027 A MX 2022004027A MX 2022004027 A MX2022004027 A MX 2022004027A
Authority
MX
Mexico
Prior art keywords
heterocycycliden
drug containing
pharmaceutical drug
acetamide derivative
dry eye
Prior art date
Application number
MX2022004027A
Other languages
English (en)
Spanish (es)
Inventor
Takeshi Tarui
Shinya Kobayashi
Original Assignee
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co filed Critical Senju Pharma Co
Publication of MX2022004027A publication Critical patent/MX2022004027A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2022004027A 2019-10-04 2020-10-02 Farmaco farmaceutico que contiene derivado de heterocicliden acetamida. MX2022004027A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019184053 2019-10-04
PCT/JP2020/037548 WO2021066144A1 (ja) 2019-10-04 2020-10-02 ヘテロシクリデンアセトアミド誘導体含有医薬

Publications (1)

Publication Number Publication Date
MX2022004027A true MX2022004027A (es) 2022-07-19

Family

ID=75338162

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022004027A MX2022004027A (es) 2019-10-04 2020-10-02 Farmaco farmaceutico que contiene derivado de heterocicliden acetamida.
MX2025005474A MX2025005474A (es) 2019-10-04 2022-04-01 Farmaco farmaceutico que contiene derivado de heterocicliden acetamida

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025005474A MX2025005474A (es) 2019-10-04 2022-04-01 Farmaco farmaceutico que contiene derivado de heterocicliden acetamida

Country Status (17)

Country Link
US (3) US12533337B2 (enExample)
EP (2) EP4545095A3 (enExample)
JP (4) JP7025094B2 (enExample)
KR (1) KR20220078604A (enExample)
CN (1) CN114585357A (enExample)
AU (2) AU2020361093B2 (enExample)
BR (1) BR112022005992A2 (enExample)
CA (1) CA3156484A1 (enExample)
DK (1) DK4043014T3 (enExample)
ES (1) ES3031607T3 (enExample)
HU (1) HUE072085T2 (enExample)
MX (2) MX2022004027A (enExample)
MY (1) MY207759A (enExample)
PH (1) PH12022550805A1 (enExample)
PL (1) PL4043014T3 (enExample)
PT (1) PT4043014T (enExample)
WO (1) WO2021066144A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022005992A2 (pt) 2019-10-04 2022-06-21 Mochida Pharm Co Ltd Fármaco contendo derivado de heterociclideno acetamida
JP7175431B1 (ja) 2021-03-30 2022-11-18 千寿製薬株式会社 ヘテロシクリデンアセトアミド誘導体含有懸濁液
EP4595959A1 (en) * 2022-09-29 2025-08-06 Senju Pharmaceutical Co., Ltd. Sterilized heterocyclidene-acetamide-derivative-containing suspension
EP4595960A1 (en) 2022-09-29 2025-08-06 Senju Pharmaceutical Co., Ltd. Combination preparation containing heterocyclidene acetamide derivative

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5621566A (en) 1979-08-01 1981-02-28 Alpha- Shokuhin Kk Preparation of bifun from homegrown rice and apparatus used for it
RU2451014C2 (ru) 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Новое производное гетероциклиден ацетамида
JP4754566B2 (ja) 2005-07-22 2011-08-24 持田製薬株式会社 新規なヘテロシクリデンアセトアミド誘導体
CN101228131B (zh) 2005-07-22 2013-01-09 持田制药株式会社 新的杂环亚基乙酰胺衍生物
TW200927192A (en) * 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
US20100210682A1 (en) * 2009-02-19 2010-08-19 Abbott Laboratories Repeated Dosing of TRPV1 Antagonists
EP2377850A1 (en) 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
WO2012045729A1 (en) * 2010-10-05 2012-04-12 Glaxo Group Limited Imidazo [1, 2 -a] pyridine and pyrazolo [1, 5 -a] pyridine derivatives as trpv1 antagonists
GB201215857D0 (en) * 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
JP6230743B1 (ja) 2017-05-31 2017-11-15 持田製薬株式会社 ヘテロシクリデンアセトアミド誘導体の結晶
JP7373909B2 (ja) 2018-04-06 2023-11-06 株式会社シマノ 変速制御装置および変速システム
BR112022005992A2 (pt) 2019-10-04 2022-06-21 Mochida Pharm Co Ltd Fármaco contendo derivado de heterociclideno acetamida

Also Published As

Publication number Publication date
PT4043014T (pt) 2025-06-09
MX2025005474A (es) 2025-06-02
AU2020361093B2 (en) 2026-04-30
JP2023011735A (ja) 2023-01-24
JP7801201B2 (ja) 2026-01-16
AU2026202464A1 (en) 2026-04-16
US20260124171A1 (en) 2026-05-07
JP2022065024A (ja) 2022-04-26
JP7025094B2 (ja) 2022-02-24
KR20220078604A (ko) 2022-06-10
EP4545095A2 (en) 2025-04-30
JP2026042857A (ja) 2026-03-11
JP7248836B2 (ja) 2023-03-29
EP4043014A1 (en) 2022-08-17
EP4545095A3 (en) 2025-07-02
JPWO2021066144A1 (ja) 2021-12-02
PL4043014T3 (pl) 2025-08-11
CN114585357A (zh) 2022-06-03
US20250134854A1 (en) 2025-05-01
EP4043014B1 (en) 2025-03-19
US20220370404A1 (en) 2022-11-24
PH12022550805A1 (en) 2023-10-02
WO2021066144A1 (ja) 2021-04-08
US12502375B2 (en) 2025-12-23
HUE072085T2 (hu) 2025-10-28
MY207759A (en) 2025-03-17
DK4043014T3 (da) 2025-06-23
US12533337B2 (en) 2026-01-27
BR112022005992A2 (pt) 2022-06-21
CA3156484A1 (en) 2021-04-08
EP4043014A4 (en) 2023-10-11
ES3031607T3 (en) 2025-07-09
AU2020361093A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
PY2054376A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
CL2022001111A1 (es) Degradadores de moléculas pequeñas de helios y procedimientos de uso
UY38403A (es) Moduladores de la alfa-1 antitripsina
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
UY39723A (es) Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador
EP3569601A3 (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
MX2022001828A (es) Formas cristalinas de moduladores del regulador de conductancia transmembrana de la fibrosis quistica (cftr).
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
MX2021006552A (es) Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita.
MX2025005474A (es) Farmaco farmaceutico que contiene derivado de heterocicliden acetamida
UY38696A (es) Moduladores de alfa-1 antitripsina
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
MX2020010469A (es) Inhibidores del atf6 y sus usos.
MX2020007947A (es) Inhibidores de erbb/btk.
CO2021009083A2 (es) Compuestos y su uso para el tratamiento de la deficiencia de α1-antitripsina
UY38096A (es) Inhibidores de arginasa y sus métodos de uso
MX2021015724A (es) Composición farmacéutica para el tratamiento de la leucemia mieloide aguda, que contiene inhibidores de flt3 y agentes quimioterapéuticos.
MX381639B (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
CL2018001408A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
MX2020011367A (es) Compuesto oxo-sustituido.
UY37412A (es) Compuestos de indazol para uso en lesiones de tendones y/o ligamentos
CL2021001090A1 (es) Tratamiento y prevención de la eyaculación precoz (ep).
AR126755A1 (es) Compuestos heterocíclicos y métodos de uso